Tag: antisense oligonucleotide
-
CNS antisense oligonucleotides — tofersen missed its clinical primary yet was approved, and eplontersen missed its and was not: same modality, opposite regulatory outcome
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All trial results, reduction figures and safety events are attributed to the sponsoring trial, company or regulator; cross-trial and cross-indication comparisons are not head-to-head. Surrogate-biomarker results (neurofilament light) are kept…
-
Tau and next-generation targets — a closer target to cognition than amyloid, yet the intervention trials keep missing the primary endpoint
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and effect-size figures are attributed to the sponsoring trial or company; several are company press releases or conference presentations rather than peer-reviewed data (noted inline). The tau-versus-amyloid comparisons…
Uthando Nethemba 